

federal procurement of products that either intentionally or unintentionally contain PFAS while minimizing any unnecessary burdens on our industry and logistics partners.

### III. Request for Operational Information

GSA seeks responses to the questions listed below. Please explain the reasoning behind your responses in detail. Also, please provide any data, studies, or other evidence that supports your response.

In your response please include your contact information, your business socio-economic category if applicable, and a little bit about your business (such as if you represent a manufacturer, distributor, reseller, or other).

To help GSA review comments efficiently, identify the question to which you are responding by its associated number and letter (e.g., "III.3a") or whether you are commenting on a topic not listed below.

1. Aside from a product's ecolabel, are there other ways to identify if a product contains PFAS?

2. Considering GSA's goal to reduce products containing PFAS, what product categories have the greatest opportunity for GSA to reduce or eliminate PFAS exposure?

3. What should GSA consider in terms of defining if a product has reduced or eliminated PFAS?

4. What product areas should GSA exclude at this time and why?

5. Are there unintended impacts GSA should anticipate?

a. If so, what mitigation strategies should GSA consider?

6. What is the potential impact on domestic manufacturing if GSA establishes PFAS reduction requirements that reduce or prohibit PFAS, or eliminate them entirely?

7. What limitations exist for you to identify PFAS in the products that you offer?

8. Would your answers to questions #6 and #7 be different if only intentionally added PFAS (or when a PFAS containing chemical is included in a product that serves an intended function in the product) was the focus of this inquiry?

9. What is the potential impact on small businesses including socio-economic small businesses if GSA establishes PFAS reduction requirements or prohibited PFAS entirely?

10. How long should GSA give contractors to reduce PFAS?

11. What type of exception process should GSA consider?

12. What information is readily available for you to determine if your products contain PFAS chemicals?

a. If there is not information readily available, what type of tools would help you determine if PFAS is present (e.g., supply chain mapping, specific ecolabels, etc.)

13. Would it be more impactful for GSA to target a specific product type or chemical signature in products to meet the goal of reducing or eliminating PFAS?

14. Are there existing industry manufacturing standards or oversight that address PFAS reduction or elimination?

### IV. Request for Economic Data and Consumer Research

Aside from the questions listed above, GSA also seeks to better understand the bigger picture regarding what industry changes are in fact feasible from an economic perspective. GSA seeks economic data and consumer research to help increase its understanding of the market. In your response please consider some of the questions highlighted below. You do not have to answer all of these in your response. The intent of the following are simply things to consider.

1. What will the estimated costs be to either reduce or eliminate PFAS within your industry?

2. Is there a large price differential between a product that contains PFAS and an alternative product?

3. How would a reduction or elimination of PFAS containing products impact your company's ability to compete?

4. To what extent is your industry already moving to better understand and reduce the presence of PFAS in products as a result of broader market forces or policies being considered or enacted by entities other than the federal government?

**Jeffrey A. Koses,**

*Senior Procurement Executive, Office of Governmentwide Policy, U.S. General Services Administration.*

[FR Doc. 2024-07927 Filed 4-15-24; 8:45 am]

**BILLING CODE 6820-61-P**

## GOVERNMENT PUBLISHING OFFICE

### Depository Library Council Meeting

**AGENCY:** U.S. Government Publishing Office.

**ACTION:** Notice of meeting.

**SUMMARY:** The Depository Library Council (DLC) will meet virtually on Thursday, May 2, 2024. The sessions

will take place from 12:30 p.m. to 5:15 p.m. (EDT). The meetings will take place online, and anyone can register to attend at <https://www.fdplp.gov/about/events-and-conferences/2024-depository-library-council-virtual-meeting>. Closed captioning will also be provided. The purpose is to discuss matters affecting the Federal Depository Library Program and its transition to a digital program. All sessions are open to the public.

**DATES:** May 2, 2024.

**Hugh Nathaniel Halpern,**

*Director, U.S. Government Publishing Office.*

[FR Doc. 2024-08040 Filed 4-15-24; 8:45 am]

**BILLING CODE 1520-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

#### Notice of Closed Meeting

Pursuant to 5 U.S.C. 1009(d), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended, and the Determination of the Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, CDC, pursuant to Public Law 92-463. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee: Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP)—PAR 20-280, Cooperative Research Agreements Related to the World Trade Center Health Program (U01); RFA-OH-24-002, Exploratory/Developmental Grants on Lifestyle Medicine Research Related to the World Trade Center Health Program (R21); RFA-OH-24-003, Exploratory/Developmental Grants Related to the World Trade Center Survivors (R21-No Applications with Responders Accepted); and RFA-OH-24-004, World Trade Center Health Program Mentored Research Scientist Career Development Award (K01).*

*Dates:* May 28-30, 2024.

*Times:* 11 a.m.-6 p.m., EDT.

*Place:* Video-Assisted Meeting.

*Agenda:* To review and evaluate grant applications.